CTRI/2022/03/041466进行中（未招募）3 期
A prospective, randomized, two-arm, double-blind, active-controlled, parallel, multicentre, non-inferiority, phase III clinical trial to assess the efficacy and safety of Naftifine hydrochloride cream 2% w/w as compared to Terbinafine hydrochloride cream 1% w/w in patients with superficial fungal infection of the skin
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients of either gender of 18 to 65 years of age (both inclusive) 2. Patients with acute symptomatic tinea corporis or tinea cruris limited to single body region and with limited involvement i.e., < 5 skin lesions with each having greatest diameter of < 5 cm
- •3. Mycological diagnosis of tinea corporis or tinea cruris confirmed by detection of fungal hyphae on a microscopic KOH test
- •4. Patients with total clinical score of at least 5
- •5. Patients willing to provide written informed consent and comply with the
- •protocol requirements
排除标准
- •1. Patients with history of hypersensitivity to naftifine or terbinafine
- •2. Patients with extensive or disseminated tinea infections
- •3. Patients with tinea infection other than tinea corporis or tinea cruris such as tinea infection of face, scalp or feet
- •4. Patients with diagnosis of tinea infection requiring systemic treatment according to the severity of lesion as judged by the investigator
- •5. Patients having skin lesions with secondary bacterial infection
- •6. Patients with other dermatological conditions which may confound the disease assessment and treatment evaluation e.g., contact dermatitis, atopic dermatitis, psoriasis, urticaria
- •7. Patients with clinically significant uncontrolled systemic diseases such as
- •gastrointestinal, cardiovascular, renal, neurological, psychiatric, endocrine or
- •hematological disorders or malignancy
- •8. Patients with immunosuppressive disorder e.g., HIV infection or patients on immunosuppressive medications e.g., systemic corticosteroids or cytotoxic drugs
- •9. Patients with hepatic dysfunction (serum transaminases >_ 3 x Upper Normal Limit) or renal dysfunction (serum creatinine >_ 2.5 mg/dl)
- •10. Patients who have used the following medications:
- •a. Topical antifungal agent within 30 days prior to enrollment
- •b. Systemic antifungal agent within 8 weeks (8 months for oral terbinafine) prior to enrollment
- •c. Topical corticosteroid on the affected area(s) within 30 days prior to enrollment
- •d. Systemic corticosteroids within 30 days prior to enrollment
- •e. Systemic antihistamine agent within 3 days prior to enrollment
- •f. Any other topical treatment on the affected area(s) within 7 days prior to enrollment
- •11. Pregnant or Lactating females; or female patients of childbearing potential unwilling to use effective contraception
- •12. Patients with history of alcohol and/or drug abuse
- •13. Participation in another clinical trial in the past 3 months prior to screening
- •14. Any other reason for which the investigator feels that the patient should not participate
研究者
相似试验
已完成
不适用
A study to evaluate the efficacy and safety of Lipoxim Fire for weight management in overweight healthy womeISRCTN74656856INNOVATION LABO60
已完成
Unknown
Efficacy of OPTIMEALTH FOOD on Gut healthImprovement of constipation symptomsDigestive SystemISRCTN16659746INNOVATION LABO SCIENCES Co., Ltd60
尚未招募
4 期
A prospective,randomized,double-blind,2-arm,active-controlled,parallel,multicentre,postmarketingclinical trial to assesstheefficacy andsafety ofRabeprazole SodiumEC Capsules20mg ascomparedtoconventionalRabeprazoleGastroResistantTablets IP20mg in patients with gastro-oesophageal reflux diseaseCTRI/2022/01/039744Zydus Healthcare Limited
招募中
3 期
A clinical study to compare the therapeutic effect and safety of Avanafil (new drug) ascompared to Sildenafil in patients with ErectileDysfunctioCTRI/2020/01/022798Zydus Healthcare Ltd
进行中（未招募）
2 期
A clinical study to assess and compare the immune response and safety of two different pentavalent vaccines (vaccine given to protect against diphtheria, tetanus, whooping cough, hepatitis B and Haemophilus influenzae) in healthy childreCTRI/2017/11/010427Cadila Healthcare Ltd